Mass. Medicaid To Establish Quantity Limit For Short-Acting Beta-2 Agonists
Executive Summary
Massachusetts Medicaid will establish a quantity limit for short-acting beta-2 agonists to encourage physicians to alter "inadequate" anti-inflammatory therapy
You may also be interested in...
Mass. Medicaid Advises Against Zyprexa First Line, But No Prior Authorization
Massachusetts Medicaid is advising physicians against use of Lilly's atypical antipsychotic Zyprexa (olanzapine) as first-line therapy
Mass. Medicaid Leukotriene Blocker Limitation Seeks To Curb Allergy Use
Oral leukotriene blocker prescriptions will require prior authorization in the Massachusetts Medicaid program in an effort to curb use of the products for allergic rhinitis
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011